Race for rituximab

If all 11 planned rituximab biosimilars make it to the market, price will determine the winner. But Novartis AG's Sandoz Ltd. unit expects that fewer than half will get to the finish line, and that means price will be only part of the equation.

Rituximab's blockbuster sales and upcoming patent expirations have made it a popular target for biosimilars companies...